Media Center Investor Relations Overview Newsroom Press Releases Company Statements InBriefs Media Center Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email InBriefs Jun 15, 2022 New data reveal residual unmet needs in young SMA patients treated with gene therapy and suggest further potential of using SPINRAZA® Read More Apr 29, 2022 Ionis amends CARDIO-TTRansform study of eplontersen Read More Mar 22, 2022 Phase 2 Study of olezarsen published in European Heart Journal Read More Mar 03, 2022 Key learnings from GENERATION HD1 study of tominersen highlighted at CHDI 2022 Read More Dec 27, 2021 Ionis initiates HALOS clinical study of Angelman syndrome Read More Nov 01, 2021 Topline results of Phase 2 clinical study support continued development of Cimdelirsen designed to treat uncontrolled acromegaly Read More Sep 20, 2021 ASCEND study to evaluate a higher dose of Ionis-discovered nusinersen in SMA patients who had less than optimal response to Evrysdi Read More May 27, 2021 Ionis launches ‘Ion-ARPA’ initiative with an eye toward revolutionizing drug discovery – again Read More Apr 06, 2021 Ionis expands distribution agreement with Sobi to include TEGSEDI® in North America Read More Jan 20, 2021 ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers Read More Jul 10, 2020 New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS Read More Jun 17, 2020 Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH Read More May 06, 2020 Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function Read More Mar 30, 2020 Ionis Statement on COVID-19 Read More Feb 27, 2020 Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference Read More
Jun 15, 2022 New data reveal residual unmet needs in young SMA patients treated with gene therapy and suggest further potential of using SPINRAZA® Read More Apr 29, 2022 Ionis amends CARDIO-TTRansform study of eplontersen Read More Mar 22, 2022 Phase 2 Study of olezarsen published in European Heart Journal Read More Mar 03, 2022 Key learnings from GENERATION HD1 study of tominersen highlighted at CHDI 2022 Read More Dec 27, 2021 Ionis initiates HALOS clinical study of Angelman syndrome Read More Nov 01, 2021 Topline results of Phase 2 clinical study support continued development of Cimdelirsen designed to treat uncontrolled acromegaly Read More Sep 20, 2021 ASCEND study to evaluate a higher dose of Ionis-discovered nusinersen in SMA patients who had less than optimal response to Evrysdi Read More May 27, 2021 Ionis launches ‘Ion-ARPA’ initiative with an eye toward revolutionizing drug discovery – again Read More Apr 06, 2021 Ionis expands distribution agreement with Sobi to include TEGSEDI® in North America Read More Jan 20, 2021 ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers Read More Jul 10, 2020 New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS Read More Jun 17, 2020 Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH Read More May 06, 2020 Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function Read More Mar 30, 2020 Ionis Statement on COVID-19 Read More Feb 27, 2020 Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference Read More
Jun 15, 2022 New data reveal residual unmet needs in young SMA patients treated with gene therapy and suggest further potential of using SPINRAZA® Read More
Mar 03, 2022 Key learnings from GENERATION HD1 study of tominersen highlighted at CHDI 2022 Read More
Nov 01, 2021 Topline results of Phase 2 clinical study support continued development of Cimdelirsen designed to treat uncontrolled acromegaly Read More
Sep 20, 2021 ASCEND study to evaluate a higher dose of Ionis-discovered nusinersen in SMA patients who had less than optimal response to Evrysdi Read More
May 27, 2021 Ionis launches ‘Ion-ARPA’ initiative with an eye toward revolutionizing drug discovery – again Read More
Apr 06, 2021 Ionis expands distribution agreement with Sobi to include TEGSEDI® in North America Read More
Jan 20, 2021 ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers Read More
Jul 10, 2020 New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS Read More
Jun 17, 2020 Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH Read More
May 06, 2020 Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function Read More
Feb 27, 2020 Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference Read More
